Synlogic stock.
On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the “Reverse Stock Split”), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Following the reverse split, shares are trading at about $3.95 this morning. SYBX stock is down 5.6% as of Thursday morning, with some 2,000 shares changing hands. For the record, the company’s ...CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...
Jun 30, 2023 · Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ... ٢٧/٠٩/٢٠٢٣ ... Synlogic (SYBX) Announces Reverse Stock Split ... Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...DJ. Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months …
May 11, 2023 · CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...
Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CISynlogic designed drug candidates to reduce levels of Phe in people with PKU using precision genetic engineering of the well-characterized probiotic E. coli Nissle. SYNB1934 reflects additional optimization to further increase productivity of Phe consumption compared to SYNB1618.CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Nov 27, 2023 · What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00.
But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ...
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ...Sep 28, 2023 · Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ... Dec 1, 2023 · Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Top Public Companies. #5. Codexis. Revenue: $69.056 million in 2020; $18.032 million in Q1 2021. Codexis on June 17 raised its 2021 investor guidance after receiving a binding purchase order from ...View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.8600 -0.0300 (-1.59%) At close: 04:00PM EDT 1.8400 -0.02 (-1.08%) After …The latest price target for . Synlogic (NASDAQ: SYBX) was reported by Chardan Capital on August 11, 2023.The analyst firm set a price target for $6.00 expecting SYBX to rise to within 12 months (a ...Get Synlogic Inc (SYBX.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
Cash runway expected into H2 2024. CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and ...Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions.
Founded Date 2014. Founders Alison Silva, Ankit Mahadevia, Dean Falb, Jim Collins, Timothy K. Lu. Operating Status Closed. Last Funding Type Post-IPO Equity. Legal Name Synlogic, Inc. Stock Symbol NASDAQ:SYBX. Company Type For Profit. Contact Email [email protected]. Phone Number (617)401-9975.$-12.72 Market Cap $18.29 M Shares Outstanding 9.19 M Public Float 4.54 M Yield SYBX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3. October 18, 2022.Share. Share. Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Stock Information for Synlogic Inc. Loading. Please wait while we ...
Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...
Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Synlogic saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 90,800 shares, a decline of 41.7% from the previous total of 155,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment.If your Synlogic shares are registered in your own name, please contact our transfer agent, American Stock Transfer & Trust Company, LLC, and inform them of your request by calling them at 1-800-937-5449 or writing them at 6201 15th Avenue, Brooklyn, NY 11219.Nov 22, 2023 · A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information.Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.Synlogic ( NASDAQ:SYBX ) First Quarter 2023 Results Key Financial Results Net loss: US$15.6m (flat on 1Q 2022). ... It does not constitute a recommendation to buy or sell any stock, ...Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Apr. 27. MT. Chardan Adjusts Price Target on Synlogic to $5.50 From $7, Keeps Buy Rating. Mar. 30. MT. Synlogic Rating Maintained at Buy But Price Target Lowered to $5.50 at Chardan Due to 'Higher Projected Future Share Count'. Mar. 30.
Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.Exhibit 10.1 . SYNLOGIC, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED . ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN . 1.1 Purpose and Scope.The purpose of the Synlogic, Inc. 2015 Employee Stock Purchase Plan, as amended, as it may be further amended from time to time, (the “Plan”) is to …Instagram:https://instagram. boh.omicbhasshow to buy cryptopunks Synlogic Stock (NASDAQ:SYBX), Quotes and News Summary benzinga.com - February 11 at 9:36 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. canopy corp news6 month treasury bills rates CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA.Synlogic Announces Reverse Stock Split Sep 27 2023; SYBX:NAQ price moved over +9.73% to 2.31 Nov 22 2023; SYBX:NAQ price falls below 15-day moving average to 1.98 at 09:52 GMT Nov 24 2023; Key statistics. ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. nvda forecast CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA.On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 3,122.66% from the current SYBX share price of $2.56.Nov 22, 2023 · A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.